Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micronised Resveratrol for Friedreich Ataxia
NCT03933163Phase 2Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- May 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resveratrol in Friedreich ataxia (FA) (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Modified Friedreich Ataxia Rating Scale at 24 weeks. Started May 2019; status: completed.
02
Drugs
resveratrol
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT03933163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933163.